Abecma denied as non-formulary by Humana?

Humana's specific coverage criteria for abecma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Abecma as Non-Formulary

Humana's formulary (drug list) is tiered, and many specialty cell therapies including CAR-T products like Abecma (idecabtagene vicleucel) may sit outside the standard formulary entirely or require separate review. A non-formulary denial does not mean the treatment is medically inappropriate or unavailable — it means coverage requires an additional step: a formulary exception or medical-necessity override. This is a routinely granted pathway for treatments with no reasonable formulary alternative.

## Your Right to Appeal

Federal law requires health plans to have an exceptions process for non-formulary drugs when there is a clinical reason a formulary alternative is inadequate. Under ACA §2719, most plans must also offer external review by an independent organization after internal appeals are exhausted. ERISA §503 requires employer-plan members receive a full-and-fair review. External review must typically be requested within four months of the final internal denial. An expedited appeal is available when delay would seriously jeopardize your health — relevant here given the urgency typical in relapsed/refractory myeloma.

## Building Your Formulary Exception Appeal

1. Identify formulary alternatives — obtain Humana's current formulary tier list and identify every multiple-myeloma agent on it. Your appeal must address why each listed alternative is not medically appropriate for this patient. 2. Document prior treatment failures — provide a chronological treatment history with dates, doses (as recorded in the chart), response, and reason for discontinuation for each prior agent. This directly supports the argument that remaining formulary options have already been tried or are contraindicated per the prescribing physician. 3. Prescriber letter addressing the exception standard — Humana's exception process typically requires a physician to attest that the non-formulary drug is medically necessary because no formulary alternative is appropriate. The letter should reference the treating physician's clinical judgment, applicable NCCN guideline recommendations, and any unique patient factors documented in the chart. 4. Clinical urgency statement — if disease is progressing rapidly, document it. Urgency supports both expedited processing and the medical-necessity argument.

## Criteria-Mapping Structure

Pull the exact language of Humana's formulary exception criteria from the plan's coverage documents or published medical policy. Create a two-column table: left column lists each exception criterion verbatim; right column cites the specific chart date, note, or test result that satisfies it. Submit the FDA-approved Abecma prescribing information as an exhibit so the reviewer can verify the approved indication aligns with the patient's diagnosis.